CMS Declines To Change Zevalin And Bexxar Off-Label Coverage Policy
This article was originally published in The Pink Sheet Daily
There is "insufficient evidence" to change current policy on off-label use of Biogen Idec's Zevalin and GSK's Bexxar in non-Hodgkin's lymphoma, the agency says in a proposed decision memo. CMS directs Medicare contractors to continue providing coverage for medically accepted off-label indications.
You may also be interested in...
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said
Pfizer will continue to support the insomnia product for up to six months.